Up-regulation of MicroRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Hung, Tzu Min ^a,b   Ho, Cheng Maw ^a,c   Liu, Yen Chun ^a,b   Lee, Jia Ling ^a   Liao, Yow Rong ^a   Wu, Yao Ming ^a   Ho, Ming Chih ^a   Chen, Chien Hung ^a   Lai, Hong Shiee ^a   Lee, Po Huang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 190B; SOMATOMEDIN C; UNCLASSIFIED DRUG; MIRN190 MICRORNA, HUMAN; TUMOR MARKER;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF 1 GENE; IMMUNOFLUORESCENCE TEST; INSULIN RESISTANCE; LIVER CELL CARCINOMA; MALE; PREDICTION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; APOPTOSIS; CASE CONTROL STUDY; CELL PROLIFERATION; COMPARATIVE STUDY; DNA MICROARRAY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; UPREGULATION;

ADULT; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84895874726     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089446     Document Type: Article

References (45)

1. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518. (Pubitemid 38868620)
2. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353. (Pubitemid 38529873)
3. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, et al. (2009) The Role of Liver-Derived Insulin-Like Growth Factor-I. Endocr Rev 30: 494-535.
4. Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GYF, Kaplan RC, et al. (2009) The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev 25: 3-12.
5. Abbas A, Grant PJ, Kearney MT (2008) Role of IGF-1 in glucose regulation and cardiovascular disease. Expert Rev Cardiovasc Ther 6: 1135-1149.
6. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease - A population-based case-control study. Circulation 106: 939-944. (Pubitemid 34925327)
7. Yu R, Yakar S, Liu YL, Lu YR, LeRoith D, et al. (2003) Liver-specific IGF-I gene deficient mice exhibit accelerated diabetes in response to streptozotocin, associated with early onset of insulin resistance. Mol Cell Endocrinol 204: 31-42. (Pubitemid 36871550)
8. Yakar S, Liu JL, Fernandez AM, Wu YP, Schally AV, et al. (2001) Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 50: 1110-1118. (Pubitemid 32374542)
9. Lee EK, Gorospe M (2010) Minireview: posttranscriptional regulation of the insulin and insulin-like growth factor systems. Endocrinology 151: 1403-1408.
10. Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, et al. (2011) Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 155: 427-434.
11. Li D, Liu X, Lin L, Hou J, Li N, et al. (2011) MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 286: 36677-36685.
12. Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, et al. (2012) Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest 92: 978-987.
13. Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX, et al. (2008) Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 376: 548-552.
14. Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, et al. (2009) Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun 381: 597-601.
15. Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, et al. (2009) MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 36: 181-188.
16. Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, et al. (2000) Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 87: 118-121. (Pubitemid 30368424)
17. Rehem RN, El-Shikh WM (2011) Serum IGF-1, IGF-2 and IGFBP-3 as Parameters in the Assessment of Liver Dysfunction in Patients with Hepatic Cirrhosis and in the Diagnosis of Hepatocellular Carcinoma. Hepatogastroenterology 58: 949-954.
18. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, et al. (2002) Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis - A prospective study. Cancer 95: 2539-2545. (Pubitemid 35424040)
19. Su WW, Lee KT, Yeh YT, Soon MS, Wang CL, et al. (2010) Association of Circulating Insulin-Like Growth Factor 1 With Hepatocellular Carcinoma: One Cross-Sectional Correlation Study. J Clin Lab Anal 24: 195-200.
20. Bonefeld K, Moller S (2011) Insulin-like growth factor-I and the liver. Liver Int 31: 911-919.
21. Hung TM, Hu RH, Ho CM, Chiu YL, Lee JL, et al. (2011) Downregulation of alpha-fetoprotein expression by LHX4: a critical role in hepatocarcinogenesis. Carcinogenesis 32: 1815-1823.
22. Haraguchi T, Ozaki Y, Iba H (2009) Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res 37: e43.
23. Boura-Halfon S, Zick Y (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 296: E581-591.
24. Cohen P (2006) The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol 7: 867-873.
25. Tikhanovich I, Cox J, Weinman SA (2013) Forkhead box class O transcription factors in liver function and disease. J Gastroenterol Hepatol 28 Suppl 1: 125-131.
26. Su TS, Liu WY, Han SH, Jansen M, Yang-Fen TL, et al. (1989) Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 49: 1773-1777. (Pubitemid 19108403)
27. Budhu A, Wang XW (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80: 1197-1213. (Pubitemid 44904957)
28. Thissen JP, Verniers J (1997) Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 138: 1078-1084.
29. DeBenedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, et al. (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I - A model for stunted growth in children with chronic inflammation. J Clin Invest 99: 643-650. (Pubitemid 27097665)
30. Fu Q, Yu X, Callaway CW, Lane RH, McKnight RA (2009) Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. FASEB J 23: 2438-2449.
31. Schober ME, Ke XR, Xing BH, Block BP, Requena DF, et al. (2012) Traumatic brain injury increased IGF-1B mRNA and altered IGF-1 exon 5 and promoter region epigenetic characteristics in the rat pup hippocampus. J Neurotrauma 29: 2075-2085.
32. Sceusi EL, Loose DS, Wray CJ (2011) Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford) 13: 369-376.
33. Adeli K (2011) Translational control mechanisms in metabolic regulation: critical role of RNA binding proteins, microRNAs, and cytoplasmic RNA granules. Am J Physiol Endocrinol Metab 301: E1051-1064.
34. Raddatz D, Ramadori G (2007) Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z Gastroenterol 45: 51-62. (Pubitemid 46202721)
35. Loeper S, Ezzat S (2008) Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord 9: 41-58.
36. Tsugane S, Inoue M (2010) Insulin resistance and cancer: epidemiological evidence. Cancer Sci 101: 1073-1079.
37. Kawaguchi T, Taniguchi E, Itou M, Sakata M, Sumie S, et al. (2011) Insulin resistance and chronic liver disease. World J Hepatol 3: 99-107.
38. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, et al. (2010) Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroentero 16: 2265-2271.
39. Sumie S, Kawaguchi T, Komuta M, Kuromatsu R, Itano S, et al. (2007) Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep 18: 545-552.
40. Miuma S, Ichikawa T, Taura N, Shibata H, Takeshita S, et al. (2009) The level of fasting serum insulin, but not adiponectin, is associated with the prognosis of early stage hepatocellular carcinoma. Oncol Rep 22: 1415-1424.
41. Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL (2012) Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res 18: 3992-3997.
42. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, et al. (2011) Clinical and prognostic implications of plasma insulin-Like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29: 3892-3899.
43. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, et al. (2012) MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 7: 195.
44. Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, et al. (2012) MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS One 7: e46045.
45. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, et al. (2010) miR-192/miR-215 influence 5-Fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 9: 2265-2275.